Symbols / VINC
VINC Chart
About
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 68.05K |
| Enterprise Value | -4.37M | Income | -22.64M | Sales | — |
| Book/sh | 0.40 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | 0.03 | P/C | — |
| EV/EBITDA | 0.18 | EV/Sales | — | Quick Ratio | 1.69 |
| Current Ratio | 1.79 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.79 | EPS next Y | -0.67 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-09-04 16:00 | ROA | -197.53% |
| ROE | -31.36% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 5.23M |
| Shs Float | 4.67M | Short Float | 2.72% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 1.43 | 52W Low | 0.00 |
| Beta | 1.57 | Avg Volume | 4.97K | Volume | 22.00 |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.01 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-54.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-08 | main | Leerink Partners | Outperform → Outperform | $2 |
| 2024-04-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-04-01 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2022-11-17 | main | Chardan Capital | — → Buy | $3 |
| 2022-08-12 | main | SVB Leerink | — → Outperform | $5 |
| 2022-06-08 | main | Cantor Fitzgerald | — → Overweight | $8 |
| 2022-06-07 | main | B. Riley Securities | — → Buy | $6 |
| 2022-06-07 | main | Chardan Capital | — → Buy | $4 |
| 2022-06-07 | main | SVB Leerink | — → Outperform | $6 |
| 2022-05-13 | main | Chardan Capital | — → Buy | $11 |
| 2022-05-13 | main | SVB Leerink | — → Outperform | $19 |
| 2022-03-30 | main | SVB Leerink | — → Outperform | $20 |
| 2022-03-30 | main | HC Wainwright & Co. | — → Buy | $28 |
| 2022-01-14 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2021-12-23 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2021-11-01 | init | SVB Leerink | — → Outperform | $24 |
| 2021-09-13 | init | Laidlaw & Co. | — → Buy | $30 |
| 2021-08-25 | init | B. Riley Securities | — → Buy | $26 |
| 2021-08-13 | main | Chardan Capital | — → Buy | $30 |
- Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan hu, 17 Apr 2025 07
- Vincerx Pharma Announces Suspension and Intent to Delist Common Stock from Nasdaq - Nasdaq hu, 17 Apr 2025 07
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - Yahoo Finance hu, 17 Apr 2025 07
- Nasdaq to delist Vincerx Pharma by April 23 - Investing.com hu, 17 Apr 2025 07
- Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire ue, 18 Mar 2025 07
- Financially struggling drugmaker's potential rescue falls apart. It now will wind down - San Francisco Business Times - The Business Journals ue, 08 Apr 2025 07
- Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace ue, 09 Apr 2024 07
- Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities - Yahoo Finance ue, 08 Apr 2025 07
- vincerx pharma cancels merger, initiates wind-down activities - Investing.com Fri, 11 Apr 2025 07
- Vincerx Pharma (VINC) Stock Price, News & Analysis $VINC - MarketBeat Wed, 06 Jan 2021 10
- symbol__ Stock Quote Price and Forecast - CNN Sun, 03 Mar 2024 11
- Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire Wed, 16 Jul 2025 07
- Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq Mon, 27 Jan 2025 08
- Business model and strategy - Vinci Mon, 02 Dec 2024 11
- Vincerx Pharma plans reverse merger with QumulusAI - Investing.com ue, 18 Mar 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -30.56M | -41.65M | -71.62M | -85.67M |
| TotalUnusualItems | 183.00K | -47.00K | 3.83M | 23.36M |
| TotalUnusualItemsExcludingGoodwill | 183.00K | -47.00K | 3.83M | 23.36M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.07M | -40.16M | -62.98M | -39.31M |
| ReconciledDepreciation | 1.09M | 915.00K | 939.00K | 340.00K |
| EBITDA | -30.37M | -41.69M | -67.78M | -62.32M |
| EBIT | -31.46M | -42.61M | -68.72M | -62.66M |
| NetInterestIncome | 472.00K | 1.25M | 664.00K | 0.00 |
| InterestIncome | 472.00K | 1.25M | 664.00K | 0.00 |
| NormalizedIncome | -30.26M | -40.11M | -66.82M | -62.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.07M | -40.16M | -62.98M | -39.31M |
| TotalExpenses | 31.46M | 42.61M | 68.72M | 62.66M |
| TotalOperatingIncomeAsReported | -31.46M | -42.61M | -71.19M | -62.66M |
| DilutedAverageShares | 1.90M | 1.06M | 1.05M | 858.80K |
| BasicAverageShares | 1.90M | 1.06M | 1.05M | 858.80K |
| DilutedEPS | -15.85 | -37.72 | -62.20 | -45.80 |
| BasicEPS | -15.85 | -37.72 | -62.20 | -45.80 |
| DilutedNIAvailtoComStockholders | -30.07M | -40.16M | -62.98M | -39.31M |
| NetIncomeCommonStockholders | -30.07M | -40.16M | -62.98M | -39.31M |
| NetIncome | -30.07M | -40.16M | -62.98M | -39.31M |
| NetIncomeIncludingNoncontrollingInterests | -30.07M | -40.16M | -62.98M | -39.31M |
| NetIncomeContinuousOperations | -30.07M | -40.16M | -62.98M | -39.31M |
| PretaxIncome | -30.07M | -40.16M | -62.98M | -39.31M |
| OtherIncomeExpense | 917.00K | 1.20M | 5.07M | 23.35M |
| OtherNonOperatingIncomeExpenses | 734.00K | 1.25M | 1.24M | -8.00K |
| SpecialIncomeCharges | 0.00 | -2.47M | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | 2.47M | 0.00 | |
| GainOnSaleOfSecurity | 183.00K | -47.00K | 6.30M | 23.36M |
| NetNonOperatingInterestIncomeExpense | 472.00K | 1.25M | 664.00K | 0.00 |
| InterestIncomeNonOperating | 472.00K | 1.25M | 664.00K | 0.00 |
| OperatingIncome | -31.46M | -42.61M | -68.72M | -62.66M |
| OperatingExpense | 31.46M | 42.61M | 68.72M | 62.66M |
| ResearchAndDevelopment | 15.49M | 28.97M | 49.84M | 40.08M |
| SellingGeneralAndAdministration | 15.98M | 13.64M | 18.89M | 22.57M |
| GeneralAndAdministrativeExpense | 15.98M | 13.64M | 18.89M | 22.57M |
| OtherGandA | 15.98M | 13.64M | 18.89M | 22.57M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.24M | 1.07M | 1.06M | 1.05M |
| ShareIssued | 2.24M | 1.07M | 1.06M | 1.05M |
| TotalDebt | 0.00 | 2.50M | 3.44M | 4.17M |
| TangibleBookValue | 2.72M | 11.22M | 47.67M | 100.32M |
| InvestedCapital | 2.72M | 11.22M | 47.67M | 100.32M |
| WorkingCapital | 1.13M | 9.13M | 46.81M | 97.92M |
| NetTangibleAssets | 2.72M | 11.22M | 47.67M | 100.32M |
| CapitalLeaseObligations | 0.00 | 2.50M | 3.44M | 4.17M |
| CommonStockEquity | 2.72M | 11.22M | 47.67M | 100.32M |
| TotalCapitalization | 2.72M | 11.22M | 47.67M | 100.32M |
| TotalEquityGrossMinorityInterest | 2.72M | 11.22M | 47.67M | 100.32M |
| StockholdersEquity | 2.72M | 11.22M | 47.67M | 100.32M |
| GainsLossesNotAffectingRetainedEarnings | 119.00K | 8.00K | -26.00K | -21.00K |
| OtherEquityAdjustments | 119.00K | 8.00K | -26.00K | -21.00K |
| RetainedEarnings | -189.19M | -159.11M | -118.95M | -55.97M |
| AdditionalPaidInCapital | 191.79M | 170.33M | 166.65M | 156.31M |
| CapitalStock | 0.00 | 0.00 | 2.00K | 2.00K |
| CommonStock | 0.00 | 0.00 | 2.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 5.28M | 7.00M | 11.62M | 17.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.39M | 2.46M | 3.44M |
| OtherNonCurrentLiabilities | 50.00K | 50.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 1.34M | 2.41M | 3.44M |
| LongTermCapitalLeaseObligation | 0.00 | 1.34M | 2.41M | 3.44M |
| CurrentLiabilities | 5.28M | 5.61M | 9.16M | 13.92M |
| OtherCurrentLiabilities | 8.00K | 191.00K | 144.00K | 6.45M |
| CurrentDebtAndCapitalLeaseObligation | 1.16M | 1.02M | 738.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 1.16M | 1.02M | 738.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 2.04M | 2.51M | |
| PayablesAndAccruedExpenses | 5.27M | 4.25M | 5.95M | 4.22M |
| CurrentAccruedExpenses | 3.24M | 1.75M | 1.88M | 2.20M |
| Payables | 2.03M | 2.50M | 4.07M | 2.02M |
| AccountsPayable | 2.03M | 2.50M | 4.07M | 2.02M |
| TotalAssets | 8.01M | 18.22M | 59.29M | 117.68M |
| TotalNonCurrentAssets | 1.59M | 3.48M | 3.32M | 5.83M |
| OtherNonCurrentAssets | 1.59M | 1.16M | 81.00K | 1.65M |
| NetPPE | 0.00 | 2.33M | 3.24M | 4.18M |
| AccumulatedDepreciation | 0.00 | -131.00K | -79.00K | -25.00K |
| GrossPPE | 0.00 | 2.46M | 3.32M | 4.21M |
| OtherProperties | 2.20M | 3.06M | 3.95M | |
| MachineryFurnitureEquipment | 0.00 | 256.00K | 256.00K | 258.00K |
| CurrentAssets | 6.41M | 14.73M | 55.96M | 111.84M |
| OtherCurrentAssets | 49.00K | 377.00K | 369.00K | 95.00K |
| RestrictedCash | 79.00K | 72.00K | 70.00K | 105.00K |
| PrepaidAssets | 254.00K | 458.00K | 1.69M | 182.00K |
| Receivables | 1.04M | 1.04M | 1.37M | 0.00 |
| OtherReceivables | 1.04M | 1.04M | 1.37M | |
| TaxesReceivable | 250.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 4.99M | 12.78M | 52.46M | 111.46M |
| OtherShortTermInvestments | 0.00 | 40.80M | 0.00 | |
| CashAndCashEquivalents | 4.99M | 12.78M | 11.66M | 111.46M |
| CashFinancial | 111.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -26.13M | -40.45M | -59.60M | -38.66M |
| IssuanceOfCapitalStock | 17.87M | 0.00 | 0.00 | 47.43M |
| CapitalExpenditure | -5.26M | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 25.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| EndCashPosition | 5.07M | 12.85M | 11.73M | 111.56M |
| BeginningCashPosition | 12.85M | 11.73M | 111.56M | 61.79M |
| EffectOfExchangeRateChanges | 135.00K | -40.00K | 71.00K | -21.00K |
| ChangesInCash | -7.92M | 1.16M | -99.90M | 49.79M |
| FinancingCashFlow | 17.99M | 114.00K | 280.00K | 88.45M |
| CashFlowFromContinuingFinancingActivities | 17.99M | 114.00K | 280.00K | 88.45M |
| ProceedsFromStockOptionExercised | 118.00K | 114.00K | 280.00K | 41.02M |
| NetCommonStockIssuance | 17.87M | 0.00 | 0.00 | 47.43M |
| CommonStockIssuance | 17.87M | 0.00 | 0.00 | 47.43M |
| InvestingCashFlow | 212.00K | 41.50M | -40.58M | -5.26M |
| CashFlowFromContinuingInvestingActivities | 212.00K | 41.50M | -40.58M | -5.26M |
| NetInvestmentPurchaseAndSale | 212.00K | 41.50M | -40.58M | 0.00 |
| SaleOfInvestment | 11.68M | 53.32M | 2.40M | 0.00 |
| PurchaseOfInvestment | -11.46M | -11.82M | -42.98M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -5.00M | ||
| PurchaseOfIntangibles | 0.00 | -5.00M | ||
| CapitalExpenditureReported | 0.00 | -258.00K | ||
| OperatingCashFlow | -26.13M | -40.45M | -59.60M | -33.40M |
| CashFlowFromContinuingOperatingActivities | -26.13M | -40.45M | -59.60M | -33.40M |
| ChangeInWorkingCapital | -178.00K | -4.19M | -1.02M | 5.61M |
| ChangeInOtherWorkingCapital | -50.00K | 50.00K | ||
| ChangeInOtherCurrentLiabilities | -1.16M | -934.00K | -738.00K | -90.00K |
| ChangeInOtherCurrentAssets | -519.00K | -1.08M | 1.37M | -1.57M |
| ChangeInPayablesAndAccruedExpense | 1.02M | -3.74M | 1.25M | 6.23M |
| ChangeInAccruedExpense | 1.49M | -2.17M | 208.00K | 4.71M |
| ChangeInPayable | -468.00K | -1.57M | 1.05M | 1.51M |
| ChangeInAccountPayable | -468.00K | -1.57M | 1.05M | 1.53M |
| ChangeInPrepaidAssets | 532.00K | 1.23M | -3.16M | 1.04M |
| ChangeInReceivables | 0.00 | 328.00K | 200.00K | |
| OtherNonCashItems | -44.00K | |||
| StockBasedCompensation | 3.47M | 3.56M | 10.06M | 23.31M |
| AmortizationOfSecurities | -211.00K | -630.00K | -292.00K | 0.00 |
| DepreciationAmortizationDepletion | 1.09M | 915.00K | 939.00K | 340.00K |
| DepreciationAndAmortization | 1.09M | 915.00K | 939.00K | 340.00K |
| Depreciation | 1.09M | 915.00K | 939.00K | 340.00K |
| OperatingGainsLosses | -183.00K | 47.00K | -6.30M | -23.36M |
| GainLossOnInvestmentSecurities | -183.00K | 47.00K | -6.30M | -23.36M |
| NetIncomeFromContinuingOperations | -30.07M | -40.16M | -62.98M | -39.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VINC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|